Art Biktarvy denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for art biktarvy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Biktarvy as Not Medically Necessary — and Why You Can Appeal

Blue Cross Blue Shield medical-necessity denials for Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine) typically occur when the prior-authorization reviewer determines that the submitted documentation does not sufficiently establish that this specific regimen is clinically required for this patient. Common triggers include: insufficient documentation of the diagnosis; lack of treatment history showing why alternative regimens are not appropriate; or a formulary-preferred HIV regimen that the plan considers therapeutically equivalent. Medical-necessity denials are appeals-friendly because they are evidence-driven — a stronger clinical record commonly reverses them.

## The Federal Appeal Framework

• ACA §2719 External Review: Available after internal appeal; filing window is typically around 180 days from denial. Check your letter for the exact deadline.
• ERISA §503 (employer-sponsored plans): Entitles you to a full-and-fair review with written statement of the reasons and plan provisions relied upon.
• Expedited review: If a gap in HIV antiretroviral therapy would seriously jeopardize your health, request expedited internal and external review simultaneously — decisions are typically required within 72 hours.

## What to Gather

1. Diagnosis and baseline documentation — chart notes confirming HIV-1 diagnosis, most recent lab results documenting viral load and CD4 count (from the chart, without asserting specific thresholds here), and current clinical status. 2. Treatment history — a complete list of prior antiretroviral regimens with start/stop dates and documented reasons for change (virologic failure, resistance testing results, tolerability issues, adherence factors). 3. Resistance testing records — genotypic or phenotypic resistance test results, if applicable, that informed the choice of Biktarvy. 4. Prescriber medical-necessity letter — should explain the clinical rationale for selecting Biktarvy for this patient specifically, addressing any formulary-preferred alternatives and why they are not appropriate. 5. BCBS's medical-necessity criteria for Biktarvy — obtain the plan's published coverage policy, copy each requirement, and respond to each with specific chart evidence.

## Criteria-Mapping Structure

Use this format in your appeal:

| BCBS Medical-Necessity Requirement | Chart Evidence That Satisfies It | |---|---| | [Paste each criterion from the plan's coverage policy] | [Cite date, note, lab, or prescriber statement that directly addresses it] |

Reference the applicable DHHS HIV treatment guidelines generically to support the prescriber's clinical judgment, without quoting specific numbers.

## Next Steps

Request a peer-to-peer review between your prescriber and the plan's medical director — this is a standard right and is especially effective for medical-necessity denials where the clinical picture is complex. Submit the full documentation package in writing. If the internal appeal is denied, file for external review immediately, noting the urgency of uninterrupted HIV therapy.